Related references
Note: Only part of the references are listed.Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone
Vanitha Sekar et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential
John O. Miners et al.
DRUG METABOLISM REVIEWS (2010)
Drug Interactions of Clinical Importance among the Opioids, Methadone and Buprenorphine, and Other Frequently Prescribed Medications: A Review
Elinore F. McCance-Katz et al.
AMERICAN JOURNAL ON ADDICTIONS (2010)
Lack of Clinically Significant Drug Interactions between Nevirapine and Buprenorphine
Elinore F. McCance-Katz et al.
AMERICAN JOURNAL ON ADDICTIONS (2010)
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
Ying-Jun Cao et al.
PHARMACOTHERAPY (2008)
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
Elinore F. McCance-Katz et al.
DRUG AND ALCOHOL DEPENDENCE (2007)
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: Validation and application
Kim Keil et al.
THERAPEUTIC DRUG MONITORING (2007)
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir
Elinore F. McCance-Katz et al.
CLINICAL INFECTIOUS DISEASES (2006)
The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry
W Huang et al.
THERAPEUTIC DRUG MONITORING (2006)
Drug-drug interactions for UDP-glucuronosyltransferase substrates:: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2004)
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients
EF McCance-Katz et al.
CLINICAL INFECTIOUS DISEASES (2003)
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma
K Keil et al.
THERAPEUTIC DRUG MONITORING (2003)
A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norBuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies
DE Moody et al.
ANALYTICAL BIOCHEMISTRY (2002)
Share Paper
